Israel’s Teva Pharmaceutical Industries has confirmed that, as previously announced, the results of the two phase III clinical trials with rasagiline in advanced Parkinson's Disease (PD) patients, which Teva is currently conducting together with H. Lundbeck A/S, are expected in the next few months.
Upon successful completion of these trials, Teva intends to submit a new drug application for the product to the US Food and Drug Administration. Teva clarifies that media reports regarding rasagiline were related to the article published in the Archives of Neurology, about the successful completion of the first phase III study with rasagiline in early PD patients, which was announced in April 2000.
Teva is among the top 35 pharmaceutical companies in the world. More than 80 percent of Teva's sales are in North America and Europe. The company develops, manufacturers and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. — (menareport.com)
© 2003 Mena Report (www.menareport.com)
